Antiviral platform

Title: PTI+: Phenotype-based biological models

Research groups: Viral Biology, Evolutionary Systems Virology and Virus Experimental Evolution

We are evaluating antivirals against SARS-CoV-2 in both the biosafety level 3 facility as well as using pseudotype virus systems. In addition, we are evaluating antivirals against additional RNA viruses, including respiratory syncytial virus, vesicular stomatitis virus, influenza, and picornaviruses.

Santiago Elena (I2SysBio, CSIC)

Ana Castro (IQM, CSIC)

Gemma Fabrias (IQAC, CSIC)

Noureddine Khiar (IIQ, CSIC)

Ana Martínez (CIB, CSIC)

Sonsoles Martín Santamaría (CIB, CSIC)

Carlos Oscar Sorzano (CNB, CSIC)

José Mª Valpuesta (CNB, CSIC)

María Jesús Pérez (IQM, CSIC)

José Fernando Díaz Pereira (CIB, CSIC)

Eduardo Rial Zueco (CIB, CSIC)

Alberto Marina Moreno y Vicente Rubio Zamora (IBV, CSIC)

Covadonga Alonso (INIA y CIB, CSIC)

Bernat Crosas (IBM, CSIC)

Luis Ángel Fernández (CNB, CSIC)

Pablo Gastaminza (CNB, CSIC)

Luis Enjuanes-Isabel Sola (CNB, CSIC)

Dolores González (IPB, CSIC)

Miguel Martín Acebes (INIA, CSIC)

European Commission – NextGenerationEU

“This contract/assignment is financed by the European Union Recovery Instrument, established by the Council Regulation (EU) 2020/2094 of 14 December 2020 establishing a European Union Recovery Instrument to support the recovery in the aftermath of the COVID-19 crisis, and regulated according to Regulation (EU) 2021/241 of the European Parliament and of the Council of 12 February 2021 establishing the Recovery and Resilience Facility”.

I2SysBio - UV-CSIC

IQM - CSIC

IQAC - CSIC

IIQ - CSIC

CIB - CSIC

CNB - CSIC

IBV - CSIC

INIA / CIB - CSIC

IBM - CSIC

IPB - CSIC

INIA - CSIC